Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.
2.

Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S, Wang X, Zhao Y, Ji Z, Zink JI, Nel AE.

ACS Nano. 2013 Feb 26;7(2):994-1005. doi: 10.1021/nn3044066. Epub 2013 Jan 4.

3.

Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis.

Yu C, Zhou M, Zhang X, Wei W, Chen X, Zhang X.

Nanoscale. 2015 Mar 19;7(13):5683-90. doi: 10.1039/c5nr00290g.

PMID:
25740312
4.

Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.

Cheng YJ, Luo GF, Zhu JY, Xu XD, Zeng X, Cheng DB, Li YM, Wu Y, Zhang XZ, Zhuo RX, He F.

ACS Appl Mater Interfaces. 2015 May 6;7(17):9078-87. doi: 10.1021/acsami.5b00752. Epub 2015 Apr 24.

PMID:
25893819
5.

Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance.

Han N, Zhao Q, Wan L, Wang Y, Gao Y, Wang P, Wang Z, Zhang J, Jiang T, Wang S.

ACS Appl Mater Interfaces. 2015 Feb 11;7(5):3342-51. doi: 10.1021/am5082793. Epub 2015 Jan 27.

PMID:
25584634
6.

Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.

Xie M, Xu Y, Shen H, Shen S, Ge Y, Xie J.

Int J Pharm. 2014 Oct 20;474(1-2):223-31. doi: 10.1016/j.ijpharm.2014.08.027. Epub 2014 Aug 19.

PMID:
25149125
7.

Galactoxyloglucan-modified nanocarriers of doxorubicin for improved tumor-targeted drug delivery with minimal toxicity.

Joseph MM, Aravind SR, George SK, Pillai KR, Mini S, Sreelekha TT.

J Biomed Nanotechnol. 2014 Nov;10(11):3253-68.

PMID:
26000385
8.
9.

In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.

Chen Y, Yang W, Chang B, Hu H, Fang X, Sha X.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):406-12. doi: 10.1016/j.ejpb.2013.06.015. Epub 2013 Jun 29.

PMID:
23816639
10.

Macrophage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In Vivo Cancer Therapy.

Xuan M, Shao J, Dai L, He Q, Li J.

Adv Healthc Mater. 2015 Aug 5;4(11):1645-52. doi: 10.1002/adhm.201500129. Epub 2015 May 8.

PMID:
25960053
11.

Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.

Tarn D, Ashley CE, Xue M, Carnes EC, Zink JI, Brinker CJ.

Acc Chem Res. 2013 Mar 19;46(3):792-801. doi: 10.1021/ar3000986. Epub 2013 Feb 6.

12.

Green Synthesis and Characterization of Monodispersed Gold Nanoparticles: Toxicity Study, Delivery of Doxorubicin and Its Bio-Distribution in Mouse Model.

Mukherjee S, Sau S, Madhuri D, Bollu VS, Madhusudana K, Sreedhar B, Banerjee R, Patra CR.

J Biomed Nanotechnol. 2016 Jan;12(1):165-81.

PMID:
27301182
13.

Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin.

Yu JJ, Lee HA, Kim JH, Kong WH, Kim Y, Cui ZY, Park KG, Kim WS, Lee HG, Seo SW.

J Drug Target. 2007 May;15(4):279-84.

PMID:
17487696
14.

Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.

Zhao Q, Liu J, Zhu W, Sun C, Di D, Zhang Y, Wang P, Wang Z, Wang S.

Acta Biomater. 2015 Sep;23:147-156. doi: 10.1016/j.actbio.2015.05.010. Epub 2015 May 15.

PMID:
25985912
15.

Multifunctional envelope-type mesoporous silica nanoparticles for pH-responsive drug delivery and magnetic resonance imaging.

Chen Y, Ai K, Liu J, Sun G, Yin Q, Lu L.

Biomaterials. 2015 Aug;60:111-20. doi: 10.1016/j.biomaterials.2015.05.003. Epub 2015 May 15.

PMID:
25988726
16.

Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect.

Son YJ, Jang JS, Cho YW, Chung H, Park RW, Kwon IC, Kim IS, Park JY, Seo SB, Park CR, Jeong SY.

J Control Release. 2003 Aug 28;91(1-2):135-45.

PMID:
12932645
17.

Amphiphilic polyelectrolyte/prodrug nanoparticles constructed by synergetic electrostatic and hydrophobic interactions with cooperative pH-sensitivity for controlled doxorubicin delivery.

Huang P, Wang W, Zhou J, Zhao F, Zhang Y, Liu J, Liu J, Dong A, Kong D, Zhang J.

ACS Appl Mater Interfaces. 2015 Mar 25;7(11):6340-50. doi: 10.1021/acsami.5b00962. Epub 2015 Mar 12.

PMID:
25746122
18.

Dendrimerlike mesoporous silica nanoparticles as pH-responsive nanocontainers for targeted drug delivery and bioimaging.

Dai L, Zhang Q, Li J, Shen X, Mu C, Cai K.

ACS Appl Mater Interfaces. 2015 Apr 8;7(13):7357-72. doi: 10.1021/acsami.5b00746. Epub 2015 Mar 24.

PMID:
25765172
19.

Preparation and evaluation of SiO2-deposited stearic acid-g-chitosan nanoparticles for doxorubicin delivery.

Yuan H, Bao X, Du YZ, You J, Hu FQ.

Int J Nanomedicine. 2012;7:5119-28. doi: 10.2147/IJN.S35575. Epub 2012 Sep 26.

20.

Enhancing Cellular Uptake and Doxorubicin Delivery of Mesoporous Silica Nanoparticles via Surface Functionalization: Effects of Serum.

Shahabi S, Döscher S, Bollhorst T, Treccani L, Maas M, Dringen R, Rezwan K.

ACS Appl Mater Interfaces. 2015 Dec 9;7(48):26880-91. doi: 10.1021/acsami.5b09483. Epub 2015 Nov 20.

PMID:
26562468

Supplemental Content

Support Center